Current financial headlines

Sharemaestro Newsreel

Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.

Showing
1–23
Headlines
23
Sources here
5
Companies here
5
Current section Switzerland Drug Manufacturers - General news
Latest

finance.yahoo.com Market update

Johnson & Johnson (JNJ)’s $5.5B Talc Settlement: Turning Point or Temporary Relief?

The World Health Organization projects that the share of the world's population aged 60 years and older will almost double from 12% in 2015 to 22% by 2050. The Population Reference Bureau expects the number of Americans aged 65 and older to climb from 58 million in 2022 to 82 million by 2050. The aging population is fueling …

Is Labcorp Holdings (LH) Fully Priced Following Oncology Approvals And Raised Outlook?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Labcorp Holdings (LH) is in focus after a series of oncology diagnostics approvals and launches, including the PGDx elio tissue complete CDx for advanced …

ROP mentioned
Sharemaestro market context Trend signal started 52 weeks +47.9% ROP stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Johnson & Johnson (JNJ) Advances Seltorexant And Expands Outpatient Cardiac Care

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Johnson & Johnson (NYSE: JNJ) is advancing its novel antidepressant Seltorexant into late stage clinical development for major depressive disorder as a potential rapid …

JNJ main company
Sharemaestro market context Trend signal active 29 weeks +21.8% · Next-week setup negative 36.2% JNJ stored weekly price path from 23 Jan 2026 to 7 Aug 2026

Chronological news

Latest headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Lilly files six lawsuits to crack down on black market retatrutide weight-loss shots

[Lilly Biotechnology Center in San Diego, California, USA.] JHVEPhoto Lilly escalated its fight against black-market retatrutide by filing six new lawsuits against U.S. sellers, including compounding pharmacies, medical spas, and online vendors, the drugmaker said Wednesday in a statement [https://seekingalpha.com/pr/20616057-lilly-calls-on-online-platforms-payment-companies-and-regulators-to-shut-down-the-illegal]. The company said retatrutide …

LLY main company
Sharemaestro market context Trend signal active 52 weeks +71.6% · Next-week setup negative 40.9% LLY stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Roche (SWX:ROG) Stock Fair Value Edges Higher As Analysts Weigh Pipeline Growth

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Roche Holding now sits on a refreshed fair value estimate of CHF 370.31, up from CHF 359.22. This gives you an updated reference point for where analysts …

RO main company ROP main company
Sharemaestro market context Trend signal started 52 weeks +43.8% RO stored weekly price path from 15 Aug 2025 to 7 Aug 2026

REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?

The going has been strong for Regeneron Pharmaceuticals REGN over the past month. Shares of this biotech giant have surged 21.9% over the said time frame, outpacing the industry's growth of 4%. The stock has also outperformed the sector and the S&P 500 Index …

RO mentioned
Sharemaestro market context Trend signal started 52 weeks +43.8% RO stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Eli Lilly and Company (LLY) vs. Novo Nordisk A/S (NVO): Is Lilly Pulling Ahead in the $100 Billion Obesity Market?

The duopoly dominating the multi-billion-dollar GLP-1 weight-loss market has moved from pharmacy shelves to the federal courtroom. Novo Nordisk A/S (NYSE:NVO) filed a lawsuit in U.S. District Court in New Jersey against Eli Lilly and Company (NYSE:LLY) on July 21, accusing its primary rival …

LLY main company
Sharemaestro market context Trend signal active 52 weeks +71.6% · Next-week setup negative 40.9% LLY stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Veeva Vault CRM Selected by Eli Lilly and Company

PLEASANTON, Calif., Aug. 11, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Eli Lilly and Company (Lilly) has committed to Veeva Vault CRM globally.Veeva Vault CRM Selected by Eli Lilly and Company Vault CRM is part of the Vault CRM Suite of …

LLY main company
Sharemaestro market context Trend signal active 52 weeks +71.6% · Next-week setup negative 40.9% LLY stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Eli Lilly's Foundayo Wins UK Approval

(RTTNews) - Eli Lilly and Company's (LLY) oral GLP-1 pill Foundayo has secured UK regulatory approval for weight management and type 2 diabetes, making the UK the first European country to clear the once-daily tablet. The decision by the Medicines and Healthcare products Regulatory …

LLY main company
Sharemaestro market context Trend signal active 52 weeks +71.6% · Next-week setup negative 40.9% LLY stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Why Eli Lilly Topped the Market Today

Key Points This market has a population of almost 60 million. While the drug isn't the first of its type to be sold in that country, it will have Lilly's considerable marketing power behind it.10 stocks we like better than Eli Lilly › Eli …

LLY main company
Sharemaestro market context Trend signal active 52 weeks +71.6% · Next-week setup negative 40.9% LLY stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Can Johnson & Johnson (JNJ) Challenge Intuitive Surgical (ISRG) After Ottava’s FDA Approval?

Johnson & Johnson (NYSE:JNJ) has officially entered the U.S. soft-tissue robotic surgery market after receiving FDA De Novo authorization for its OTTAVA robotic surgical system. The authorization represents an important milestone for J&J's MedTech ambitions, but the company is entering a market in which …

JNJ main company
Sharemaestro market context Trend signal active 29 weeks +21.8% · Next-week setup negative 36.2% JNJ stored weekly price path from 23 Jan 2026 to 7 Aug 2026

ChemoMetec enters collaboration agreement with Roche Diagnostics

Chemometec A/S ANNOUNCEMENT NO. 311 After entering a Letter of Intent with Roche Diagnostics in February 2026, aiming to pursue a collaboration with the goal of creating synergies between the parties' solutions in the field of bioprocess monitoring, ChemoMetec and Roche Diagnostics have today …

RO main company ROP main company
Sharemaestro market context Trend signal started 52 weeks +43.8% RO stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Lineage Cell Therapeutics Q2 Earnings Call Highlights

Key Points Interested in Lineage Cell Therapeutics, Inc.? Here are five stocks we like better. Pipeline progress: Lineage advanced preclinical programs in corneal disease, Type 1 diabetes and hearing loss, while Roche and Genentech continued optimizing surgical delivery for the lead OpRegen retinal therapy. …

ROP mentioned
Sharemaestro market context Trend signal started 52 weeks +47.9% ROP stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Johnson & Johnson Has Increased Its Dividend for 64 Consecutive Years. Here's How Much $10,000 Invested in the Dividend King Pays Annually.

Key Points Few companies have a longer track record of uninterrupted dividend growth. This streak is likely to be prolonged well into the foreseeable future. While still an income stock, Johnson & Johnson is also being priced somewhat like a growth stock.10 stocks we …

JNJ main company
Sharemaestro market context Trend signal active 29 weeks +21.8% · Next-week setup negative 36.2% JNJ stored weekly price path from 23 Jan 2026 to 7 Aug 2026

LLY Q2 Deep Dive: Key Products and Pipeline Expansion

Global pharmaceutical company Eli Lilly (NYSE:LLY)reported Q2 CY2026 results topping the market's revenue expectations , with sales up 47.7% year on year to $22.97 billion. The company's full-year revenue guidance of $86 billion at the midpoint came in 0.6% above analysts' estimates. Its non-GAAP …

LLY main company
Sharemaestro market context Trend signal active 52 weeks +71.6% · Next-week setup negative 40.9% LLY stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Eli Lilly (LLY) Gains FDA Breakthrough Nod As Olomorasib Cancer Trial Broadens

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Eli Lilly (NYSE: LLY) reported that its KRAS G12C inhibitor olomorasib received FDA Breakthrough Therapy designation for advanced pancreatic cancer in patients with …

LLY main company
Sharemaestro market context Trend signal active 52 weeks +71.6% · Next-week setup negative 40.9% LLY stored weekly price path from 15 Aug 2025 to 7 Aug 2026

BofA points to the Eli Lilly market that could outsize the U.S.

Eli Lilly (LLY) posted a second-quarter result strong enough to shift the debate around its stock. For months, the debate centered on one worry: a slow start for its new obesity pill. That worry did not disappear in the second quarter, but it stopped …

LLY main company
Sharemaestro market context Trend signal active 52 weeks +71.6% · Next-week setup negative 40.9% LLY stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Eli Lilly and Company Q2 Earnings Call Highlights

Key Points Interested in Eli Lilly and Company? Here are five stocks we like better. Lilly reported 48% year-over-year revenue growth in Q2 2026, with MOUNJARO and ZEPBOUND generating $14.9 billion in combined sales. The company raised its full-year revenue outlook to $85 billion–$87 …

LLY main company
Sharemaestro market context Trend signal active 52 weeks +71.6% · Next-week setup negative 40.9% LLY stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem

Eli Lilly (NYSE: LLY) is already the leader in the weight-loss market thanks to Zepbound, the best-selling medication in this space. However, the drugmaker has been making headlines with its next-gen anti-obesity medicine, retatrutide. Eli Lilly recently announced that it will request approval from …

LLY main company
Sharemaestro market context Trend signal active 52 weeks +71.6% · Next-week setup negative 40.9% LLY stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Roche Stock Jumps as Morgan Stanley Sees Drug Breakout

This article first appeared on GuruFocus. Roche Holding (RHHBY), the Swiss pharmaceutical and diagnostics giant, got a major Wall Street vote of confidence after Morgan Stanley upgraded the stock to Overweight from Equal Weight and hiked its ADR price target to $63 from $46. …

RO main company ROP main company
Sharemaestro market context Trend signal started 52 weeks +43.8% RO stored weekly price path from 15 Aug 2025 to 7 Aug 2026

Johnson & Johnson (JNJ) Reaches $5.5 Billion Talc Settlement To Close Years Of Lawsuits

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Johnson & Johnson (NYSE: JNJ) agreed to a US$5.5b settlement to resolve tens of thousands of talc baby powder lawsuits. The deal ends decades of …

JNJ main company
Sharemaestro market context Trend signal active 29 weeks +21.8% · Next-week setup negative 36.2% JNJ stored weekly price path from 23 Jan 2026 to 7 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context